Showing 2091-2100 of 5643 results for "".
- Lovell and DefEYE Partner to Expand Access to Biovance Ocular Biologics Across Federal Healthcare Systemshttps://modernod.com/news/lovell-government-services-and-defeye-partner-to-expand-access-to-biovance-ocular-biologics-across-federal-healthcare-systems/2484164/Lovell Government Services and DefEYE, the provider of Biovance decellularized basement membranes for ocular use, announced a partnership to serve federal healthcare systems, including the Veterans Health Administration, the Department of Defense Military
- NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Modelhttps://modernod.com/news/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/2484162/NurExone Biologic announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. The study, conducted in collaboration
- J&J to Present New Data Demonstrating Superiority of Acuvue Oasys Max 1-Day for Astigmatism at AAOpthttps://modernod.com/news/jj-to-present-new-data-demonstrating-superiority-of-acuvue-oasys-max-1-day-for-astigmatism-at-aaopt/2484158/Johnson & Johnson announced new clinical data demonstrating significantly higher end-of-day comfort and stronger overall patient preference for the Acuvue Oasys Max 1-Day for Astigmatism contact lenses compared to Dailies Total1 for Astigmatism.
- Kala Halts Development of Investigational PCED Eye Drop After Phase 2b Trial Fails to Meet Endpointshttps://modernod.com/news/kala-halts-development-of-investigational-pced-eye-drop-after-phase-2b-trial-fails-to-meet-endpoints/2484150/Kala Bio said it is ceasing development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform after its phase 2b trial evaluating KPI-012 in persistent corneal epithelial defect (PCED) did not meet its primary or secondary efficacy endpoints.
- Formycon Expands European Footprint for Aflibercept Biosimilar FYB203 with Horus Pharma Dealhttps://modernod.com/news/formycon-expands-european-footprint-for-aflibercept-biosimilar-fyb203-with-horus-pharma-deal/2484146/Formycon announced that Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea biosimilar FYB203 (aflibercept), has entered into a new semi-exclusive license agreement with Horus Pharma. The deal grants Horus the right to
- FDA Grants Fast Track Designation to Sanofi’s Investigational Gene Therapy for Wet AMDhttps://modernod.com/news/fda-grants-fast-track-designation-to-sanofis-investigational-gene-therapy-for-wet-amd/2484142/The FDA has granted fast track designation to Sanofi's SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA&rs
- Roche Receives CE Mark for Contivue Port Delivery Platform with Susvimo in Wet AMDhttps://modernod.com/news/roche-receives-ce-mark-for-contivue-port-delivery-platform-with-susvimo-in-wet-amd/2484134/The European Union (EU) has granted CE mark for Roche's Port Delivery Platform containing Susvimo, which will be branded as Contivue in the EU. Contivue provides sustained ocular drug delivery for patients living with wet age-related macular
- FDA Grants Fast Track Designation to Aldeyra’s ADX-2191 for Retinitis Pigmentosahttps://modernod.com/news/fda-grants-fast-track-designation-to-aldeyras-adx-2191-for-retinitis-pigmentosa/2484124/The FDA has granted Fast Track Designation for Aldeyra Therapeutics' ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa (RP). The FDA’s Fast Track progra
- AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Diseasehttps://modernod.com/news/aavantgarde-bio-announces-fda-fast-track-designation-for-aavb-039-for-the-treatment-of-stargardt-disease/2484122/AAVantgarde Bio announced that the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational New Drug application for AAVB-039 was cleared to proceed by the FDA. St
- Vision Advocates Rally to Defend National Eye Institute from Funding Cuts and Consolidation Threatshttps://modernod.com/news/vision-advocates-rally-to-defend-national-eye-institute-from-funding-cuts-and-consolidation-threats/2482913/Vision science and eye care organizations are mobilizing efforts to combat proposals circulating in Washington to slash federal vision funding and consolidate the National Eye Institute (NEI) into a broader institute on brain and dental research.